JENNINGS POLICY STRATEGIES for GENERIC PHARMACEUTICAL ASSOCIATION
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 21, 2008 | $40,000 | Replaced |
| 1st Quarter - Report (this page) | Apr 20, 2009 | $40,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Average Manufacturers Price/AMP including H.R. 6331 Any matters relating to access to generic drugs
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE HAYES | HEALTH COUNSEL, US SENATOR EVAN B AYH |
| CHRISTOPHER JENNINGS | — |
Health Issues HCR
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE HAYES | HEALTH COUNSEL, US SENATOR EVAN BAYH |
| CHRISTOPHER JENNINGS | — |
Pharmacy PHA
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE HAYES | HEALTH COUNSEL, US SENATOR EVAN BAYH |
| CHRISTOPHER JENNINGS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.